Schebo COVID 19 Quick Test
Made in Germany, Schebo's Covid-19 Rapid Test can check a patient for the Coronavirus antibodies in just 15 minutes. By checking for two Corona antibodies through a patient's self-taken blood sample, the test can identify current and previous infections in patients, as well as levels of immunity. While most accurate Corona tests require laboratory equipment which can delay results for several hours to days, the Corona Virus Rapid Test comes with the test cassette, the test buffer solution, and the pipettes to extract a patient's blood and quickly perform the test in almost any environment. While there have been other tests in China as well as other countries that have surfaced with similar rapid tests methods, none have proven to be accurate enough for screening public patients and providing proper results. The German quality Schebo Covid-19 Antibody Rapid Test has over 97.5% sensitivity, as well as over 99.5% specitivity for both IGM and IGG antibodies. Prior to the release of the test, many clinical trials, controls, and sample studies were conducted in order to assure maximum quality results. With the all new CoronaVirus Rapid Test, screening patients will no longer involve long waits, large costs, and inaccurate results. Our test allows professionals to quickly screen any patients with symptoms as well as patients who would like to test for antibodies to determine levels of immunity. At US Ophthalmic, we are putting all our resources to fight this global pandemic; we know that this test will help us overcome this challenge by keeping patients properly diagnosed and safe.
* Box of 20 Tests
$100.00
 |
Development of the Covid-19 pandemic At the end of December 2019, Chinese public health authorities reported several cases of acute respiratory syndrome in Wuhan City, Hubei province, China. Chinese scientists soon identified a novel coronavirus as the main causative agent. The disease is now referred to as Coronavirus Disease 2019 (COVID-19), and the causative virus is called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It is a new strain of coronavirus that has not been previously identified in humans. |
|||||||||||
 |
Common symptoms of Infection The most common signs of infection are fever, cough, shortness of breath, muscle / joint pain, sore throat, headache, nausea and vomiting. In more severe cases, infection can lead to pneumonia, severe acute respiratory syndrome, kidney failure and even death. Recent studies have also concluded that loss of scent and taste can be indications of a developing infection of the disease. Infection of disease tends to develop stronger symptoms and poses greater risk to the elderly and to those with pre-existing medical conditions. |
|||||||||||
 |
How Covid-19 Spreads The CDC has reported Covid-19 a highly contagious and fast spreading disease. The main transmission takes place via droplets which arise when coughing and sneezing. These droplets are absorbed by the other person through the mucous membranes of the nose, mouth and possibly the eye. A transmission through contaminated surfaces cannot be ruled out, especially in the immediate vicinity of the infected person. |
|||||||||||
 |
How the Schebo Rapid test Detects Antibodies for Covid-19 The Schebo SARS-CoV-2-Quick is based on the immuno-chromatographic method. The SARS-CoV-2 IgM/IgG specific antibodies are detected by the SARS-CoV-2 recombinant antigen and the monoclonal anti human IgM/IgG antibody. SARS-CoV-2 IgM/IgG in the sample reacts with the SARS-CoV-2 recombinant antigen bound to gold particles. This complex migrates along the membrane and reaches the IgM/IgG test lines which have a monoclonal anti human IgM/IgG antibody against SARS-CoV-2 IgM/IgG complex attached. When the result is positive, the gold-labelled SARS-CoV-2 recombinant antigen-antibody complex binds to the IgM/IgG test line and a pink color develops. When the result is negative, the sample does not contain any SARS-CoV-2 recombinant antigen-antibody complex that can bind to the IgM/IgG test line, so no color becomes visible. Development of a control line (C) guarantees that sample application and migration have taken place correctly and that the test has been properly performed. |
|||||||||||
 |
Benefits of the ScheBo®•SARS-CoV-2 Quick™ IgM/IgG * Combined antibody test with high accuracy for the simultaneous detection of SARS-CoV-2 IgM and IgG * IgM detection to indicate an acute SARS-CoV-2 infection * IgG detection to indicate a past SARS-CoV-2 infection * High sensitivity and specificity * Easy to perform * Sample material: whole blood (from fingertips or veins), serum or plasma * Rapid test results after 15 minutes * CE approval as medical device * No additional equipment needed |
|||||||||||
|
HOW TO WORKS? PRE-SCREENING |
||||||||||||
 |
||||||||||||
|
HOW TO WORKS? Detection Period 15 MINUTES • Easy operation without requirement of any Doctor or Professional Nurse • No special equipment storage and transportation conditions required • Works with whole blood, serum, and plasma • Tests for 2 antibodies IgM and IgG simultaneously • Instant Field screening 98%+ACCURACY |
||||||||||||
|
||||||||||||
 |
||||||||||||
|
||||||||||||
|
PERFORMANCE CHARACTERISTICS Sensitivity and Specificity. A retrospective study was carried out with 226 samples from the First Affiliated Hospital of Anhui Medical University, including 78 samples of other respiratory tract infections, 108 samples of healthy individuals, and 40 samples of clinically confirmed COVID-19 patients. All samples were tested with the ScheBo. The re-sults of detection and clinical diagnosis of SARS-CoV-2 IgM and IgG were statistically analyzed by kappa consistency analysis. |
||||||||||||
 |
||||||||||||
 |
||||||||||||
 |
||||||||||||
|
EXPECTED VALUES A study with 40 confirmed COVID-19 patients was performed with Squebo test kit at different times after symptoms have occured, the positive rate of the IgM/IgG antibody test results were as follows: |
||||||||||||
 |
||||||||||||
 |
DIAGNOSTIC PROCESS It is widely accepted that IgM provides the first line of defence during viral infections, followed by the generation of adaptive, high anity IgG responses for long term immunity and immunological memory. Therefore testing of COVID-19 IgM and IgG antibodies is an efective method for the rapid diagnosis of COVID-19 infection. Furthermore, detection of COVID-19 IgM antibodies tends to indicate a recent exposure to COVID-19, whereas detection of COVID-19 IgG antibodies indicates a later stage of infection. Thus, this combined antibody test could also provide information on the stage of infection. |
|||||||||||
 |
KIT COMPONENTS * 20 Test Cassettes * 20 Pipettes * 1 Sample Buffer * 1 Instruction for use SIZE OF BOX: 3 x 5 x 6 inch |
|||||||||||
Click here to see the brochure
